nach oben

Erschienen in:

23.02.2017 | Topic Review

Molecular markers in glioma

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Gliomas are the most malignant and aggressive form of brain tumors, and account for the majority of brain cancer related deaths. Malignant gliomas, including glioblastoma are treated with radiation and temozolomide, with only a minor benefit in survival time. A number of advances have been made in understanding glioma biology, including the discovery of cancer stem cells, termed glioma stem cells (GSC). Some of these advances include the delineation of molecular heterogeneity both between tumors from different patients as well as within tumors from the same patient. Such research highlights the importance of identifying and validating molecular markers in glioma. This review, intended as a practical resource for both clinical and basic investigators, summarizes some of the more well-known molecular markers (MGMT, 1p/19q, IDH, EGFR, p53, PI3K, Rb, and RAF), discusses how they are identified, and what, if any, clinical relevance they may have, in addition to discussing some of the specific biology for these markers. Additionally, we discuss identification methods for studying putative GSC’s (CD133, CD15, A2B5, nestin, ALDH1, proteasome activity, ABC transporters, and label-retention). While much research has been done on these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature. Furthermore, it is unlikely that the investigator will be able to utilize one single marker to prospectively identify and isolate GSC from all, or possibly, any gliomas.

Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed

Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173CrossRefPubMed

Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110CrossRefPubMedPubMedCentral

Freije WA et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18):6503–6510CrossRefPubMed

Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812CrossRefPubMedPubMedCentral

McNamara MG, Sahebjam S, Mason WP (2013) Emerging biomarkers in glioblastoma. Cancers 5(3):1103–1119CrossRefPubMedPubMedCentral

Alentorn A et al (2015) Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther 15(8):955–962CrossRefPubMed

Cohen AL, Colman H (2015) Glioma biology and molecular markers. Cancer Treat Res 163:15–30CrossRefPubMed

Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62(15):4364–4368PubMed

10.

Patel M et al (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21(9):1247–1266CrossRefPubMed

11.

Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefPubMed

12.

Gupta K, Salunke P (2012) Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 138(12):1971–1981CrossRefPubMed

13.

Nakagawachi T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22(55):8835–8844PubMed

14.

Riemenschneider MJ et al (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120(5):567–584CrossRefPubMedPubMedCentral

15.

Horbinski C et al (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14(6):777–789CrossRefPubMedPubMedCentral

16.

Ichimura K et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347CrossRefPubMedPubMedCentral

17.

Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773CrossRefPubMedPubMedCentral

18.

Balss J et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602CrossRefPubMed

19.

Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67(1):1–15CrossRefPubMed

20.

Sugawa N et al (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87(21):8602–8606CrossRefPubMedPubMedCentral

21.

Nathanson DA et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166):72–76CrossRefPubMed

22.

Karsy M et al (2015) A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 38(3):E4CrossRefPubMed

23.

Mao H et al (2012) Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Investig 30(1):48–56CrossRef

24.

Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21–35CrossRefPubMed

25.

Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135(5):558–568PubMed

26.

Lam PY et al (2000) Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 14(1):28–32CrossRefPubMed

27.

Cancer Genome Atlas Research (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068CrossRef

28.

Aldape K et al (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848CrossRefPubMed

29.

Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467–470CrossRefPubMed

30.

Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405CrossRefPubMed

31.

Jones DT et al (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28(20):2119–2123CrossRefPubMedPubMedCentral

32.

Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10:128CrossRefPubMedPubMedCentral

33.

Cho DY et al (2013) Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 22(4):731–739CrossRefPubMed

34.

Seymour T, Nowak A, Kakulas F (2015) Targeting aggressive cancer stem cells in glioblastoma. Front Oncol 5:159CrossRefPubMedPubMedCentral

35.

Lathia JD et al (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217CrossRefPubMedPubMedCentral

36.

Hemmati HD et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100(25):15178–15183CrossRefPubMedPubMedCentral

37.

Bradshaw A et al (2016) Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg 3:21PubMedPubMedCentral

38.

Trepant AL et al (2015) Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. Tumor Biol 36(3):1943–1953CrossRef

39.

Dahlrot RH et al (2013) What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 6(3):334–348PubMedPubMedCentral

40.

Bao S et al (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 68(15):6043–6048CrossRefPubMedPubMedCentral

41.

Yanagisawa M (2011) Stem cell glycolipids. Neurochem Res 36(9):1623–1635CrossRefPubMed

42.

Lagadec C et al (2014) The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells 32(1):135–144CrossRefPubMedPubMedCentral

43.

Lathia JD et al (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5):421–432CrossRefPubMedPubMedCentral

44.

Shmelkov SV et al (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37(4):715–719CrossRefPubMed

45.

Schmohl JU, Vallera DA, CD133, selectively targeting the root of cancer. Toxins, 2016. 8(6)

46.

Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828PubMed

47.

Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401CrossRefPubMed

48.

Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5(6):563–581PubMedPubMedCentral

49.

Xia CL et al (2003) A2B5 lineages of human astrocytic tumors and their recurrence. Int J Oncol 23(2):353–361PubMed

50.

Auvergne RM et al (2013) Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3(6):2127–2141CrossRefPubMedPubMedCentral

51.

Chen J et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522–526CrossRefPubMedPubMedCentral

52.

Lendahl U, Zimmerman LB, McKay RD (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585–595CrossRefPubMed

53.

Xie L et al (2015) Characterization of nestin, a selective marker for bone marrow derived mesenchymal stem cells. Stem Cells Int 2015:762098CrossRefPubMedPubMedCentral

54.

Kastan MB et al (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75(10):1947–1950PubMed

55.

Storms RW et al (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96(16):9118–9123CrossRefPubMedPubMedCentral

56.

Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1):17–25CrossRefPubMed

57.

Munakata K et al., Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clin Cancer Res, 2016

58.

Vlashi E et al (2009) In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101(5):350–359CrossRefPubMedPubMedCentral

59.

Lagadec C et al (2014) Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer 14:152CrossRefPubMedPubMedCentral

60.

Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45(8):872–877CrossRefPubMed

61.

Szakacs G et al (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234CrossRefPubMed

62.

Bleau AM et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3):226–235CrossRefPubMedPubMedCentral

63.

Hambardzumyan D, Squatrito M, Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10(6):454–456CrossRefPubMed

64.

Deleyrolle LP et al (2011) Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134(Pt 5):1331–1343CrossRefPubMedPubMedCentral

65.

Zeng L et al (2016) Label-retaining assay enriches tumor-initiating cells in glioblastoma spheres cultivated in serum-free medium. Oncol Lett 12(2):815–824PubMedPubMedCentral

Titel: Molecular markers in glioma
Publikationsdatum: 23.02.2017
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2379-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular markers in glioma

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Management of GBM: a problem of local recurrence

Immunotherapy and radiation in glioblastoma

State of the art: the evolving role of RT in combined modality therapy for GBM

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches

The evolving role for re-irradiation in the management of recurrent grade 4 glioma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie